Exercise and GLP-1 RA on Insulin Secretion

NCT04383197 · Unknown status

Last updated 2026-05-28

This clinical trial tests how exercise and a medication called GLP-1 receptor agonist affect insulin production in adults with type 2 diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 30 people Planned (estimated).

Who can join Ages 40–70 · all sexes

Timeline Started 2019-12 · est. completion 2022-08

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT04383197 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the effect of endurance exercise on insulin secretory capacity, alone or in addition to treatment with the glucagon-like-peptide receptor agonist semaglutide, in patients with type 2 diabetes.

Treatments tested

Endurance exercise training Behavioral

Ergometer cycling at 70 % of VO2 max, 45 minutes, 3 times a week
Semaglutide Drug

3 months of therapeutic treatment with semaglutide

Main thing measured	Insulin secretion
Sponsor	University of Copenhagen
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04383197 ↗